8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Mar 9, 2026·SEC
Biofrontera Inc.(BFRI)Earnings, Financials & Key Ratios
BFRI•NASDAQ
$1.16
Price updated Jul 6, 2026
AboutBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Show more
- Revenue$42M+11.8%
- EBITDA-$8M+48.4%
- Net Income-$11M+40.7%
- EPS (Diluted)-0.90+72.0%
- Gross Margin78.65%+56.9%
- EBITDA Margin-19.85%+53.9%
- Operating Margin-21.93%+52.5%
- Net Margin-25.26%+46.9%
- ROE-141.3%+63.3%
BFRI Price & Volume
Biofrontera Inc. (BFRI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Challenge Commercialization Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and financing risk
Key Thesis Takeaways
- Biofrontera faces a precarious path to profitability as its inconsistent revenue growth, which fluctuated between a 22.5% contraction and 36.2% expansion in recent quarters, fails to cover high commercialization costs.
- While gross margins have improved to 81.8% as of 2026Q1, the company's inability to achieve operating leverage remains a primary concern for long-term sustainability.
- Investors should monitor the company's limited $6.3M cash position, which may necessitate dilutive capital raises to support ongoing operations given the persistent quarterly net losses.
Verdict Logic
the company's structural inability to generate positive free cash flow, evidenced by the $4.8M net loss in 2026Q1, presents a significant risk to liquidity and shareholder value.
BFRI Growth Metrics
Biofrontera Inc. (BFRI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years17.21%
3 Years13.3%
TTM13.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM43.45%
Return on Capital
10 Years-90.56%
5 Years-98.77%
3 Years-118.34%
Last Year-68.4%
BFRI Recent Earnings
Biofrontera Inc. (BFRI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.41-256.5%
$0.12
Rev
$10M-1.6%
$10M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.50+72.4%
$0.29
Rev
$17M+5.9%
$16M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.59+1.7%
$0.60
Rev
$7M-56.7%
$16M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.57-26.7%
$0.45
Rev
$9M-5.4%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.41vs $0.12-256.5% | $10Mvs $10M-1.6% |
| Q2 2026 | Mar 19, 2026 | $0.50vs $0.29+72.4% | $17Mvs $16M+5.9% |
| Q4 2025 | Nov 12, 2025 | $0.59vs $0.60+1.7% | $7Mvs $16M-56.7% |
| Q3 2025 | Aug 13, 2025 | $0.57vs $0.45-26.7% | $9Mvs $10M-5.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Biofrontera Inc. (BFRI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.16 | $14.85M | -1.29 | 11.8% | -25.26% | -141.3% | — | |
| $7.22 | $198.71M | -15.36 | 10.2% | -14.82% | -35.57% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $3.08 | $1.07B | 36.11 | 0.57% | 3.74% | 4.75% | — | |
| $0.75 | $97.84M | -4.72 | -10.02% | -2.03% | -9.41% | — |
Compare BFRI vs Peers
Biofrontera Inc. (BFRI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BFRI SEC Filings & Documents
Biofrontera Inc. (BFRI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BFRI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BFRI Frequently Asked Questions
Biofrontera Inc. (BFRI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Biofrontera Inc.'s revenue?
Biofrontera Inc. (BFRI) reported $43.2M in revenue for fiscal year 2025. This represents a 65% increase from $26.2M in 2019.
How fast is Biofrontera Inc. growing?
Biofrontera Inc. (BFRI) grew revenue by 11.8% over the past year. This is steady growth.
Is BFRI profitable?
Biofrontera Inc. (BFRI) reported a net loss of $11.1M for fiscal year 2025.
Dividend & Returns
What is BFRI's return on equity?
Biofrontera Inc. (BFRI) has a return on equity (ROE) of -141.3%. Negative ROE indicates the company is unprofitable.
What is Biofrontera Inc.'s free cash flow?
Biofrontera Inc. (BFRI) had negative free cash flow of $9.3M in fiscal year 2025, likely due to heavy capital investments.